Categories
World News

Augmented actuality agency Nreal targets IPO inside 5 years, CEO says

SHANGHAI — Nreal, a Chinese company making glasses for so-called augmented reality experiences, is looking to go public within five years, its CEO told CNBC.

“We’re thinking this is really a major tech market and really looking forward to what’s going to happen in the next 10 to 15 years. Very exciting – I think its more like ’06, ’07 of the smartphone business,” Chi Xu, CEO of Nreal said.

“We see a lot of good opportunities and, definitely, we’re thinking the market size is going to be massive. And we have this opportunity and we want to take this to the final end.”

He said an initial public offering could come in “less than 5 years.”

The company’s flagship product is a pair of lightweight glasses called Nreal Light, which has been released in a handful of markets including South Korea and Japan. Nreal says its glasses allow users to experience “mixed reality” where digital images are superimposed over the real world.

The Nreal Light connects to a smartphone. One of the immediate uses frees people from being tied to their small smartphone screens.

“Whatever you’re displaying in the cellphone screen in front of you, you put that in front of your face, into a massive screen, and that can be 3D, that can be ultra-high definition,” Xu said.

An attendee tries a pair of Nreal mixed-reality glasses at the MWC Shanghai exhibition in Shanghai, China, on Tuesday, Feb. 23, 2021.

Qilai Shen | Bloomberg | Getty Images

Nreal’s ambitions pit it against technology giants that see a bright future in augmented reality. Apple CEO Tim Cook has called AR the “next big thing” and the iPhone giant is reportedly working on a headset. Facebook, Microsoft, Google and other technology companies are all investing in AR.

But current headsets on the market are expensive and often bulky. Nreal is hoping its portable nature will appeal to consumers. The price varies by market depending on how it is distributed. For example, in Japan the headset costs around $700. But in South Korea, the device can be purchased through a telecom operator’s plan which subsidizes the headset to around $300.

Business model

Nreal has a platform for developers to create apps for the headset’s operating system called Nebula.

“It’s very similar to what Apple has been doing for smartphone,” Xu said. “We offer a platform where people use that for different kinds of experiences and developers — they can deploy, they can develop different content onto the field.”

Apple not only makes money from sales of its iPhones and other hardware but it also gets revenue from commissions off its App Store.

Nreal has some notable backers. Kuaishou, the short-video platform in China and iQiyi, a video streaming service, are among the company’s investors. Xu said Nreal would be working with both Kuaishou and iQiyi.

“As we mentioned, not only are we going to provide the hardware. We want to bundle different services with the glasses. So take video for example, whether it’s a long video or short video. We’re thinking glasses are a much better terminal to experience the video in,” the CEO said.

“So that’s why we’ll be working with those giants, really working on the new interface.”

Categories
Politics

Kamala Harris fundraiser Jon Henes to launch company advisory agency

Vice President Kamala Harris’ former national campaign finance chair is opening a strategic advisory firm that will aim, in part, to guide corporations and C-suite executives through handling social justice and politically charged issues.

Jon Henes, a longtime corporate restructuring attorney at the prominent law firm Kirkland & Ellis, plans to launch his new New York-based firm around Labor Day, according to people briefed on the matter.

The firm is planning to hire at least 15 people at first, and it could expand operations to Washington, D.C., Los Angeles and San Francisco, a person said.

The advisory firm will have a multipronged approach, including a corporate strategic advisory arm that would do the traditional counseling on hiring practices such as union inclusion. It will also have a team that will focus on environmental, social and corporate governance, and workplace diversity, equity and inclusion, these people said.

The people cited in this story declined to be named because details for the new venture have yet to be finalized.

A Kirkland & Ellis press release announcing Henes’ departure noted he was on his way to starting a strategic advisory firm but provided no further details.

“Over the past few years, in addition to my work at Kirkland, I have had the opportunity to immerse myself in the world of politics and policy, opening my eyes to the critical business need for helping CEOs navigate the convergence of business, finance and law with social justice, diversity, inclusion and politics,” Henes said in the release. “It is bittersweet to leave my Kirkland colleagues, many of whom I think of as family, but I’m excited to embark on this new chapter of my career.”

He did not return CNBC’s follow-up requests for comment.

The firm’s launch comes as corporations experience pushback from consumers and employees over their stances on social justice and environmental issues.

After voting laws that have been deemed restrictive by critics were passed in Georgia, corporations felt pressured to respond. Several did, including Major League Baseball, which moved its All-Star Game from Georgia to Colorado.

In a recent example of the pressure, Toyota halted giving campaign contributions to Republican lawmakers who challenged the results of the election.

The competition for advisory firms like these is fierce, but many, especially those run by people with high-level contacts, are often successful.

Teneo, which was co-founded by Bill Clinton’s former right-hand man, Doug Band, has been known as an influential advisory group that has links to massive corporations.

The same can be said for WestExec Advisors, which has seen over 15 consultants head into the Biden administration, according to reporting by The Intercept and The American Prospect. Antony Blinken co-founded WestExec and is now secretary of State.

One of the other expected leaders of Henes’ firm is Alvin Tillery, according to the sources. Tillery is an associate professor at Northwestern University and director of the school’s Center for the Study of Diversity and Democracy.

Tillery has experience running an advisory firm of his own. He is the founder of Analytic Insights Consulting, which, according to the firm’s website, “advises corporate, nonprofit, and governmental entities seeking to build more diverse, equitable, and inclusive work environments.” The firm’s listed previous clients include MGM International Resorts, Baker Demonstration School, the City of Evanston, and Exelixis.

If Tillery and Henes reach an official agreement, Tillery would continue his work at the school and will have a leadership role at the newly created advisory business, a person said. Analytic Insights Consulting is potentially folded into the new firm founded by Henes, this person noted.

Tillery did not respond to a request for comment.

Henes was Harris’ national finance chair while she was running for president during the 2020 election, helping her raise at least $400,000 before he started raising money for Joe Biden, CNBC previously reported.

Henes also led fundraising efforts both for Democrat Jaime Harrison’s bid for South Carolina’s U.S. Senate seat last year and former Citigroup executive Ray McGuire’s campaign for New York mayor in the Democratic primary this year.

While the Harris, Harrison and McGuire runs were unsuccessful, his fundraising efforts were key for Henes in developing contacts and potential partners and clients for his new firms. Harris went on to be vice president, and Harrison is the new chair of the Democratic National Committee.

Henes also developed strong corporate ties when he worked for clients as a restructuring and corporate governance advisor. Kirkland’s website shows that his past clients include Ion Media, Avaya and J.Jill.

Categories
Politics

TJ Ducklo will get new job at PR agency after quitting White Home amid scandal

White House Deputy Press Secretary TJ Ducklo holds a sheet of paper with names and headshots of reporters on it during a press conference at the White House in Washington on Feb. 8, 2021.

Carlos Barria | Reuters

TJ Ducklo, the former deputy press secretary for President Joe Biden, joins an influential public relations and crisis communications firm months after he left the White House for allegedly threatening to destroy a reporter’s career.

Ducklo now works for Risa Heller Communications, which is operated by its namesake Risa Heller. She was once the communications director for Senate Majority Leader Chuck Schumer, DN.Y., and worked for former New York Governor David Paterson.

She confirmed the attitude towards the political newsletter Punchbowl News.

“Like all of us, he made mistakes, faced the consequences and learned from them,” she told the outlet that published the announcement on Wednesday morning. “We are incredibly excited to have him on our team, where he is already leading high-profile crisis and emissions engagements in NY, LA and around the world and becoming a trusted advisor to corporate leaders.”

Heller didn’t respond to requests for comment Tuesday after CNBC asked if their company had discontinued Ducklo.

According to the company’s website, Ducklo started working there in June.

CNBC policy

Read more about CNBC’s political coverage:

According to Buzzfeed, Heller also worked for Ivanka Trump, the daughter of former President Donald Trump.

Ducklo, who has lung cancer, was briefly suspended from his post in the White House before resigning because he reportedly told a reporter, “I will destroy you”. He also reportedly made derogatory and misogynistic comments to the reporter, who is a woman.

He apologized after the reported incident in February.

People who first told CNBC about Ducklo’s new employer prior to the Punchbowl announcement declined to be named to speak freely about an unannounced hiring.

The Heller office specializes in corporate and crisis communication, runs campaigns for non-profit organizations and supports issues such as issue advocacy and regulatory affairs. With its connections to Biden and administration, Ducklo could be of service to Heller’s customers on the regulatory front.

Ducklo and Heller did not return repeated requests for comment, and in particular did not deny anything CNBC asked them about the former White House deputy press secretary.

Many of the company’s other executives come from a variety of backgrounds, including previous roles at Fox News, the New York Post, and Senator Amy Klobuchar’s office.

Few of the employees listed on the Heller website have previous connections with Biden. Crains New York reports that Heller’s company represents marquee clients such as Major League Soccer’s New York City FC, Airbnb and the Metropolitan Opera.

Before Ducklo left the Biden administration, he was known as one of the president’s closest communications advisors. He was previously Biden’s campaign spokesman.

Ducklo also has experience outside of politics, including serving as communications director for NBC News.

Categories
Health

Gene testing agency 23andMe trades increased after Branson SPAC merger

Anne Wojcicki, co-founder and CEO of 23andMe (right) celebrates with 23andMe employees after remotely ringing the NASDAQ opening bell at the headquarters of DNA technology company 23andMe in Sunnyvale, California, USA on June 17, 2021.

Peter DaSilva | Reuters

The newest trade on the exchange is “ME”.

23andMe, a personalized medicine and home genetic test kit company, went public on Thursday through a merger with a Richard Branson SPAC, VG Acquisition Corp..

23andMe stock rose 21% on the Nasdaq on its first day of trading as a publicly traded company.

Founded by Anne Wojcicki – the former wife of Google founder Sergey Brin who was an early investor in the company – 23andMe was founded 15 years ago. Together with Ancestry, it helped advance the idea that genetic testing is not just a medical field, but a big consumer business. His home test kits, which enabled people to find out their genetic profiles and ancestry by sending some saliva in the mail, ushered in a new era of personalized medicine, albeit not without controversy.

23andMe, a five-time CNBC Disruptor 50 company, had no straight or sure path to success as a publicly traded company.

It was reviewed by the FDA earlier in its history; Questions about consumer privacy continue to arise as genetic information is collected from millions of people; has run into financial difficulties in recent years when the market for personalized genetic testing seemed saturated; Skepticism about the basis of their gene-based risk analysis remains controversial; and as it delves deeper into drug development, a gap in its current customer base and underlying genetic data between a mostly European genetic profile and an underrepresentation of many minorities and ethnic groups.

“It will take time … to really make sure we get all communities to participate in the research,” Wojcicki said Thursday morning in an interview with CNBC’s TechCheck. “You can’t make discoveries in a population if those people aren’t part of it. We need the right customers and we have to present the product to them in the right way.”

Wojcicki says the company has big things ahead of it for both its consumer and drug discovery and development platforms. Approximately 80% of 23andMe’s 11 million members now choose to share their genetic information (anonymized) for drug development research.

“Our genetics represent all of life on this planet and we have the opportunity to understand what it means and, in doing so, it will improve your own life, but it will also contribute to all kinds of research discoveries,” said Wojcicki.

She says the controversy over the medical usefulness of the information won’t go away once it is put into the hands of consumers, and it ranges from critical, clinical information such as mutations in the gene that causes breast cancer, BRCA, to “more controversial” genetic ones Information on variants of Alzheimer’s disease. Some people at higher risk of blood clots choose to walk around more during flights based on their 23andMe reports.

However, she added that consumers have shown that they want this information to help them make decisions.

In the case of Alzheimer’s risk, she said, “This information … really affects how they live their lives … how they retire … plan to get older.”

Her own 10-year-old son used the company’s lactose intolerance analysis to diagnose his abdominal pain, and Wojcicki herself said, although she was reluctant to talk about her personal use of the product, as the daughter of a woman who suffered from breast cancer and who a higher risk of illness, the information influences their decision to drink that “leisure glass of wine”.

“Over the past 15 years we’ve built the infrastructure so we can take off to prove to consumers that we can get the information and understand it without a healthcare professional,” she said.

In her opinion, the key to the future is that consumers want to use the information not only to change their lives, but also to contribute to drug discovery.

23andMe has 40 programs ongoing on its drug discovery platform.

“We want them to have a truly personalized health experience and … benefit the human genome when all of this aggregated data is turned into therapeutic programs,” said Wojcicki. “When I think about the future of therapeutics, the next five years are really about moving these programs forward and getting them into the clinic.”

The company also recently launched a subscription product to bring more content and services to consumers who want to take extra steps after their genetic reports.

“We reach thousands of people who call the customer care team each week and want to know how this information can be used and applied to lead healthier longer lives,” she said.

The IPO market already set an annual record for the transaction volume of $ 171 billion in 2021, and only halfway through the year. Average first day trading profits on trades this year were over 40%. Although both the traditional IPO market and SPAC yields have cooled in recent months, the Renaissance IPO ETF and CNBC SPAC Index have been negative since the start of 2021, with a continuation of last year’s big gains since the start of the year. Meanwhile, concerns about SPAC deals have increased, and some high profile SPACs like Branson’s Virgin Galactic and electric vehicle maker Lordstown Motors have shown high levels of volatility.

Nonetheless, Branson and other investors plan to bring another space company, the satellite internet service Virgin Orbit, to the public via a SPAC in the coming weeks.

This history has been updated for the company’s closing price on the first day of trading on Thursday.

SIGN IN for our weekly original newsletter that goes beyond the list and offers a closer look at CNBC Disruptor 50’s companies and the founders who continue to innovate in all areas of the economy.

Categories
World News

Marketing campaign launched to get Peter Thiel’s agency out of NHS

Peter Thiel, co-founder and chairman of Palantir Technologies Inc., pauses during a news conference in Tokyo, Japan, on Monday, Nov. 18, 2019.

Kiyoshi Ota | Bloomberg | Getty Images

LONDON — A campaign is being launched to try to stop U.S. tech giant Palantir from working with the U.K.’s National Health Service.

The “No Palantir in Our NHS” campaign — launched at an event on Thursday — comes after Palantir partnered with the NHS on a Covid-19 “Data Store.” The project was designed to help the government and health service use data to monitor the spread of the virus.

Foxglove, which describes itself as a tech-justice nonprofit, is leading the campaign, while over 50 other organizations working on civil liberties, anti-racism, migrant justice and public health have also backed it.

“We got dozens of organizations to realize and agree that this company has no place in the NHS in the long term,” Cori Crider, the lawyer who co-founded Foxglove, told CNBC on Wednesday.

Palantir, which has been criticized by privacy campaigners and human rights groups on multiple occasions, declined to comment when contacted by CNBC. A spokesperson for the NHS did not respond.

What is Palantir?

Founded in 2003 by tech entrepreneurs including billionaire Peter Thiel — a Facebook board member who reportedly donated $1.25 million to Donald Trump’s presidential campaign — Palantir sells software that’s designed to help public and private organizations analyze huge quantities of data and pull out meaningful patterns and connections.

Since its inception, the $45 billion publicly listed company has supported spy agencies, border forces and militaries, with the finer details of contracts often kept a closely guarded secret.

In April 2018, Bloomberg published an article headlined: “Palantir Knows Everything About You.”

Named after the fictional “seeing stones” in “Lord of the Rings,” Palantir has been linked to everything from efforts to track down undocumented immigrants in the United States to the development of unmanned drones for bombings and intelligence.

“Their background has generally been in contracts where people are harmed, not healed,” Crider said.

Clive Lewis, a Labour Party member of Parliament and one of the campaign’s backers, accused Palantir of having an “appalling track record.”

“It’s built its business supporting drone and missile strikes, immigration raids and arrests, not the delivery and care of medicine,” Lewis told CNBC. “It’s got a questionable agenda, and I think that will have a negative impact on patient trust, particularly among minoritized communities who may feel a threat from big government.”

Palantir — which has been trying to grow its European business in recent years — has a significant presence in London’s Soho neighborhood, with hundreds of employees across multiple offices in the area.

Covid-19 Data Store

The Covid-19 Data Store project, which involves Palantir’s Foundry data management platform, began in March 2020 alongside other tech giants as the government tried to slow the spread of the virus across the U.K. It was sold as a short-term effort to predict how best to deploy resources to deal with the pandemic.

The contract was quietly extended in December when the NHS and Palantir signed a £23 million ($34 million) two-year deal that allows the company to continue its work until December 2022.

The NHS was sued by political website openDemocracy in February over the contract extension. “December’s new, two-year contract reaches far beyond Covid: to Brexit, general business planning and much more,” the group said.

The NHS Covid-19 Data Store contract allows Palantir to help manage the data lake, which contains everybody’s health data for pandemic purposes.

“The reality is, sad to say, all this whiz-bang data integration didn’t stop the United Kingdom having one of the worst death tolls in the western world,” said Crider. “This kind of techno solution-ism is not necessarily the best way of making an NHS sustainable for the long haul.”

Patient data is “pseudonymized” before it is processed by Palantir’s software as part of an effort to protect patient privacy. The data management technique involves switching the original data set, with an alias or pseudonym. However, it is a reversible process that allows for re-identification in the future if necessary and some have questioned whether it’s enough. Palantir may argue that it isn’t interested in the patient data itself and that it only provides the platform that allows the NHS to analyze the data.

While Palantir is processing the patient data, the NHS remains the data owner, limiting what Palantir can do with it.

Pivot to health

There have been some signs that government appetite for limitless spend on security has started to wane and Palantir may have lost a couple of deals as a result, Crider said, pointing to a report in The Guardian that highlights some of the difficulties the EU’s law agency had with Palantir’s software.

Crider believes the firm has been trying to find new sources of government contracts beyond security as a result. “They hit on a new possibility, which was health data,” she said.

The company was reportedly lobbying officials from the U.K. Department of Trade as well as health executives back in 2019. But it struggled to secure any contracts.

When the pandemic hit, however, the laws changed so that data sharing was done in a mandatory way and for the first time in U.K. history everyone’s data was pooled into a huge lake. Procurement rules were also reportedly changed. “Palantir pounced and they managed to get in,” Crider said, adding that there was no bid or competitive tender.

Palantir’s interest in health was highlighted again on Thursday when it emerged in a Financial Times report that the company has taken a strategic stake in British health firm Babylon as part of a $4.2 billion blank-check deal to take the start-up public in the U.S.

Babylon CEO Ali Parsa told the newspaper that “nobody” has brought some of the tech that Palantir owns “into the realm of biology and healthcare.” Parsa, whose app offers a variety of health care services to 24 million patients, added: “Their knowledge of healthcare can overhaul what we could do [together]. We wanted to take … the day to day biometrics of the human body and be able to construct a more pre-emptive image, by building a digital twin of each of us.”

A boy runs past a mural supporting the NHS, by artist Rachel List, on the gates of the Hope & Anchor pub in Pontefract, Yorkshire, as the UK continues in lockdown to help curb the spread of the coronavirus.

Danny Lawson | Getty Images

Crider believes the U.K. is at an inflexion point when it comes to health data.

From July 1, the NHS is planning to pool the full medical histories of 55 million patients in England into a single database that will be available to academic and third parties for research and planning purposes. Patients have until June 23 to opt out. Campaigners said Friday the “data grab” violates patient trust and they’re threatening to take legal action.

“The British public need to realize that we are now coming into a period where the future of the NHS health data, and the health data settlement of this country, is now kind of up for grabs and up for debate,” Crider said. “Companies have seen it for a while. Palantir don’t want to monetize the data they want to monetize the infrastructure, but there are other companies who absolutely do want to monetize access to the data.”

Categories
Health

Medical hashish agency backed by Snoop Dogg begins buying and selling in London

Recording artist Snoop Dogg speaks on stage on day one of TechCrunch Disrupt SF 2015 at Pier 70 on September 21, 2015 in San Francisco, California.

Getty Images

LONDON – Oxford Cannabinoid Technologies, happily endorsed by rapper Snoop Dogg and tobacco giant Imperial Brands, launched on the London Stock Exchange on Friday.

The British company, which specializes in developing pain relieving cannabinoid drugs, grossed £ 16.5 million ($ 23.4 million) in gross proceeds on its IPO with a starting market value of just over £ 48 million ($ 69 million) .1 million USD).

The share price hovered around 5p on Friday lunchtime after opening near 8p.

Snoop Dogg, whose real name is Calvin Broadus Jr., has invested in several cannabis startups, including OCT, through his venture capital firm Casa Verde. His firm has also supported plant-based food companies like Outstanding Foods and tech names like Klarna, Robinhood, and Reddit.

Cannabinoids are naturally occurring compound chemicals found in the cannabis sativa plant and are commonly used for medicinal purposes to treat symptoms such as chronic pain.

OCT’s strategy is to develop cannabinoid drugs for the non-addictive treatment of painful conditions. CEO John Lucas told CNBC on Friday the company plans to use the proceeds of its IPO to develop four new drugs.

“The key here is getting cannabinoids into the hands of patients and the way you do that happens through the drug development process,” Lucas told CNBC’s Squawk Box Europe.

“With medical cannabis, the problem is that doctors can’t prescribe it, so we want a drug that we can get into the hands of doctors, into the hands of patients.”

In its listing announcement, OCT said its “primary market focus is on the total addressable pain market, valued at at least £ 42.5 billion through the commercialization of the first drug manufactured by OCT, currently expected in 2027.”

Categories
Business

Sanofi-GlaxoSmithKline Covid Vaccine Exhibits Promise, Agency Says

Sanofi, the French pharmaceutical company, announced Monday that it will move the experimental Covid-19 vaccine it is developing with GlaxoSmithKline to a late-stage study after the shot provoked strong immune responses in an interim study in volunteers.

The results are encouraging news for a vaccine that has fallen behind in development and so far has disappointed those who expect it to be vital in fighting the pandemic. If the vaccine can be available in the last three months of this year, as the developers hope, it could continue to play a pivotal role as a booster, as well as an initial vaccination, in developing countries where vaccination pace is lagging.

The vaccine suffered a major setback in December when its developers announced that it did not appear to work well in older adults and that they had plans to test it in a Phase 3 study, the pivotal test in assessing the vaccine’s effectiveness. would have to move.

However, the companies modified the vaccine and began testing it in February in a Phase 2 study that enrolled more than 700 volunteers in the US and Honduras between the ages of 18 and 95. Sanofi said the vaccine raised no safety concerns and produced a strong immune response across age groups, suggesting it was successfully optimized.

Sanofi announced the results in a statement, saying it plans to publish the results in a medical journal soon.

Sanofi and GSK have much more vaccine development experience than some of their previously approved competitors. The two companies took a more established approach than those used in other, more rapidly developed Covid vaccines. Their shot is based on viral proteins made with engineered viruses that grow in insect cells. GSK supplies the Sanofi vaccine with an adjuvant, a component used in many vaccines to boost the immune response.

The Sanofi and GSK vaccine was one of six vaccines selected for funding through Operation Warp Speed, the Trump administration’s effort to accelerate vaccine development. Last summer, the federal government agreed to give companies $ 2.1 billion to develop and manufacture the vaccine, against 100 million doses once the shot was done.

Sanofi also has delivery agreements with the European Union and Canada. It was also agreed to ship 200 million doses to Covax, the program to deliver vaccines to middle and low income countries that is grappling with a shortage of expected doses. Sanofi also announced plans to help manufacture the approved vaccines from Pfizer-BioNTech, Moderna and Johnson & Johnson.

Sanofi said the Phase 3 trial of its vaccine will begin in the coming weeks and will enroll more than 35,000 adult volunteers around the world. Two formulations of the vaccine are being tested, one to prevent the original strain of the virus and the other for variant B.1.351, which was first observed in South Africa and against which some vaccines appear to be less effective.

Su-Peing Ng, Sanofi’s global medical director for vaccines, told journalists on Monday that the company believed it would be “operationally quite difficult” to enroll unvaccinated participants in the Phase 3 study because the vaccination rate was in many countries. Still, she said, vaccine doses are still scarce in many parts of the world, pointing to Latin America and Asia as places the company may want to enroll volunteers.

The company said that shortly after the Phase 3 trial begins, it will test whether its vaccine can boost immune responses in people who had been vaccinated with approved vaccines months earlier. These booster studies are expected to enroll volunteers in well-vaccinated parts of the world, including the US and Europe.

Sanofi and GSK said last year they are preparing to produce 1 billion cans a year. Thomas Triomphe, Sanofi’s global director of vaccines, said Monday that if the vaccine turns out to work, the company’s production would depend on the needs of the world this year.

The vaccine “has the potential to be a booster of choice for many nations and many different platforms”.

Categories
World News

China autonomous driving agency WeRide valued at $3.Three billion after funding

A fleet of WeRide robot axles is shown. The company has been testing its robot axis in the southern Chinese city of Guangzhou since 2019.

We drive

GUANGZHOU, China – WeRide autonomous driving company raised new funds to value the company at $ 3.3 billion.

The Nissan-backed startup did not disclose the amount it raised, but said it was “hundreds of millions” of dollars from venture capital investors such as IDG Capital and Sky9 Capital. A number of other supporters and existing investors attended the round.

Tony Han, CEO of WeRide, said in a statement that the new funds will be used for research and development as well as commercialization “with the aim of ensuring comprehensive autonomous mobility in the future.”

WeRide is one of the many China-based companies aggressively pushing to be a global leader in autonomous driving.

In 2019, a Robotaxi project was opened in the southern Chinese city of Guangzhou, where the headquarters are located. The public has been able to use the service in a specific area of ​​the city since last year.

In April, WeRide received approval from the California Department of Motor Vehicles (DMV) to conduct driverless tests on public roads in San Jose.

The company competes with other startups like Pony.ai, which raised $ 267 million in November, and AutoX. Larger tech companies, including internet giant Baidu and hail-fighting company Didi, are also exploring the space.

WeRide’s final round of funding is based on an injection of $ 310 million in January.

WeRide’s CEO previously told CNBC that he predicts that large-scale application of robotaxis will occur between 2023 and 2025. He said WeRide will start making money from the business from 2025.

The company doesn’t make cars. Instead, the autonomous drive systems are sold to other car manufacturers.

Categories
Business

Offshore wind agency to work with researchers and sort out blade waste

This file photo taken on July 31, 2018 shows workers checking the quality of newly manufactured wind turbine blades at a factory in China.

AFP | Getty Images

A collaboration between science and industry is expected to focus on recycling fiberglass products, which could ultimately help reduce waste from wind turbine blades.

In an announcement on Thursday, the University of Strathclyde, based in Glasgow, Scotland, said it had signed a memorandum of understanding with Aker Offshore Wind and Aker Horizons.

Among other things, the trio will work together to scale and commercialize a laboratory-developed process that involves recycling fiberglass-reinforced polymer composites used in wind turbine blades.

According to the university, the system focuses on the “heat recovery and post-treatment of glass fibers” from glass fiber-reinforced polymer composite scrap with the end result “glass fibers of almost virgin quality”. The idea is that with this system the composite waste can be reused.

“This is a challenge not just for the wind power industry, but for all industries that rely on GRP materials to manufacture and manufacture them,” said Liu Yang, head of the Advanced Composites Group at the University of Strathclyde, in a statement.

“Maintaining and redistributing the energy contained in the fibers is critical to moving towards a circular economy,” he added.

What to do with wind turbine blades when they are no longer needed is an industry headache. This is because the composite blades can prove difficult to recycle, which means many end up in landfill at the end of their lifespan.

As the number of wind turbines on the planet increases, the problem becomes even greater. According to Strathclyde, blade waste could reach 400,000 tons per year by 2030.

In recent years, a number of companies in the industry have tried to find solutions to the problem.

For example, last December, GE Renewable Energy and Veolia North America signed a “multi-year contract” to recycle blades removed from onshore wind turbines in the US.

In an announcement at the time, GE Renewable Energy said the blades would be crushed at a Veolia North America facility in Missouri before being “used as a substitute for coal, sand and clay in cement factories in the United States.”

In January 2020, the Danish wind energy giant Vestas announced that it wanted to produce zero-waste wind turbines by 2040.

Categories
Business

He Constructed a $10 Billion Funding Agency. It Fell Aside in Days.

Until recently, Bill Hwang sat on one of the greatest – and perhaps least known – fortunes on Wall Street. Then his luck ran out.

Mr. Hwang, a 57-year-old veteran investor, managed $ 10 billion through his private investment firm Archegos Capital Management. He borrowed billions of dollars from Wall Street banks to build huge positions in some American and Chinese stocks. By mid-March, Mr. Hwang was the financial force behind $ 20 billion worth of ViacomCBS stock. This made him the largest single institutional shareholder in the media company. Few knew of his overall exposure as the shares were held primarily through complex financial instruments called derivatives, created by the banks.

That all changed in late March after ViacomCBS’s shares fell sharply and lenders began demanding their money. When Archegos couldn’t pay, they confiscated its assets and sold them, resulting in one of the biggest implosions for an investment firm since the 2008 financial crisis.

Almost overnight, Mr. Hwang’s personal wealth dwindled. It’s a story as old as Wall Street itself, where the right combination of ambition, skill, and timing can generate fantastic profits – only to collapse in a moment when conditions change.

“This whole matter is an indication of the loose regulatory environment in recent years,” said Charles Geisst, a Wall Street historian. “Archegos was able to hide its identity from regulators using the best example of shadow trading through banks.”

The collapse of Mr. Hwang’s company had ripples. Two of his bank lenders have reported losses in the billions. At ViacomCBS, the share price has halved within a week. The U.S. Securities and Exchange Commission has opened a preliminary investigation into Archegos, two people familiar with the matter, and market observers are calling for closer scrutiny of family offices like Mr. Hwangs – the wealthy’s private investment vehicles that control an estimated trillion dollars in assets. Others are calling for more transparency in the market for the types of derivatives being sold to Archegos.

Mr. Hwang declined to comment on the article.

It’s a proverbial American story from rags to riches. Born in South Korea, Hwang moved to Las Vegas in 1982 as a high school student. He spoke little English and his first job was as a cook at a McDonald’s on the Strip. Within a year his father, a pastor, had died. He and his mother moved to Los Angeles, where he studied economics at the University of California at Los Angeles, but was distracted by the excitement of nearby Santa Monica, Hollywood, and Beverly Hills.

“I always blame people who started UCLA in such a beautiful neighborhood,” he said in a 2019 speech to parishioners for the Promise International Fellowship, a church in Flushing, Queens. “I couldn’t go to school that often, to be honest.”

He barely graduated, he said, with a Masters of Business Administration from Carnegie Mellon University in Pittsburgh. He then worked for about six years at a South Korean financial services company in New York and finally got a plum job as an investment advisor for Julian Robertson, the respected stock investor whose Tiger Management, founded in 1980, was considered a pioneer of hedge funds.

After Mr. Robertson closed the New York Fund to outside investors in 2000, he helped found Mr. Hwang’s own hedge fund, Tiger Asia, which was focused and growing rapidly in Asian stocks, and at one point managed $ 3 billion for outside investors Investors.

Mr. Hwang was known to swing big. He made big, focused bets on stocks in South Korea, Japan, China and elsewhere, using copious amounts of borrowed money or leverage to add to his returns or destroy his positions.

He was more humble in his personal life. The house he and his wife Becky bought in an upscale suburb of Tenafly, New Jersey, is worth about $ 3 million – modest by Wall Street standards. A religious man, Mr. Hwang founded the Grace and Mercy Foundation, a New York-based nonprofit that sponsors Bible reading and religious book clubs, growing its net worth from $ 70 million to $ 500 million in less than a decade. The foundation has donated tens of millions of dollars to Christian organizations.

“He gives ridiculous amounts,” said John Bai, co-founder and managing partner of equity research firm Fundstrat Global Advisors, who has known Mr. Hwang for about three decades. “But he does it in a very humble, humble, not boastful way.”

In business today

Updated

April 2, 2021, 3:58 p.m. ET

However, he took risks in his investment approach and his company violated regulators. In 2008, Tiger Asia lost money when the investment bank Lehman Brothers filed for bankruptcy at the height of the financial crisis. The next year, Hong Kong regulators accused the fund of using confidential information obtained to trade some Chinese stocks.

In 2012, Mr. Hwang reached a civil settlement with US securities regulators in a separate insider trading investigation and was fined $ 44 million. That same year, Tiger Asia pleaded guilty to federal insider trading fees in the same investigation and returned money to its investors. Mr. Hwang was banned from managing public funds for at least five years. The supervisory authorities officially lifted the ban last year.

Shortly after Tiger Asia closed, Mr. Hwang Archegos, named after the Greek word for leader or prince, opened. The new company, which invested in both US and Asian stocks, resembled a hedge fund, but its assets consisted entirely of the personal assets of Mr. Hwang and certain family members. The deal protected Archegos from regulatory scrutiny due to a lack of public investors.

Goldman Sachs, who had loaned him to Tiger Asia, initially refused to deal with Archegos. JPMorgan Chase, another prime broker or large retail company lender, also stayed away. But as the company grew, eventually reaching more than $ 10 billion in net worth, its lure became irresistible to someone familiar with the size of its holdings. Archegos traded stocks on two continents, and banks could charge substantial fees for the deals they helped create.

Goldman later changed course and became a prime broker for the company alongside Credit Suisse and Morgan Stanley in 2020. Nomura also worked with him. JPMorgan refused.

Earlier this year, Mr. Hwang had loved a handful of stocks: ViacomCBS, which had high hopes for its emerging streaming service; Discovery, another media company; and Chinese stocks, including e-cigarette company RLX Technologies and education company GSX Techedu.

ViacomCBS traded at around $ 12 a little over a year ago and rose to around $ 50 by January. Mr. Hwang continued to amass his stake, said people familiar with his trading, through complex positions he arranged with banks called “swaps,” which gave him economic exposure and returns – but not actual ownership – the share provided.

By mid-March, when the stock moved toward $ 100, Mr. Hwang had become the single largest institutional investor in ViacomCBS, according to these individuals and a New York Times analysis of public filings. People valued the position at $ 20 billion. However, since Archegos’ stake was backed by borrowed money, it had to pay the banks to cover the losses or be quickly wiped out if ViacomCBS shares unexpectedly reversed.

On Monday March 22nd, ViacomCBS announced plans to sell new shares to the public. The deal hoped to generate $ 3 billion in new cash to fund its strategic plans. Morgan Stanley carried out the deal. When bankers wooed the investing community, they reckoned that Mr. Hwang would be the anchor investor who would buy at least $ 300 million of the stock, said four people involved in the offer.

But sometime between the announcement of the deal and its closing on Wednesday morning, Mr. Hwang changed his plans. The reasons are not entirely clear, but RLX, the Chinese e-cigarette company, and GSX, the education company, had developed in Asian markets around the same time. His decision resulted in ViacomCBS’s fundraiser ending up with $ 2.65 billion in new capital, well below the original target.

ViacomCBS executives were unaware of Mr. Hwang’s tremendous impact on the company’s share price, nor that he had canceled plans to invest in the stock offering until two people close to ViacomCBS said it was closed. They were frustrated to hear about it, people said. At the same time, investors who had received a higher-than-expected participation in the new share offering and discovered that it fell short, sold the share, which lowered the price even further. (Morgan Stanley declined to comment.)

On Thursday March 25th, Archegos was in critical condition. ViacomCBS’s falling share price triggered “margin calls” or demands for additional cash or assets from its prime brokers, which the company was unable to meet in full. Hoping to buy time, Archegos convened a meeting with its lenders and asked for patience while it quietly unloaded assets, said a person close to the company.

These hopes were dashed. Sensing the impending failure, Goldman began selling Archegos’ assets the next morning, followed by Morgan Stanley to get their money back. Other banks soon followed.

When ViacomCBS stock hit the market that Friday due to the massive sales by the banks, Mr. Hwang’s fortune plummeted. Credit Suisse, which acted too slowly to calm the damage, announced the possibility of substantial losses. Nomura announced losses of up to $ 2 billion. Goldman finished dissolving his position but made no loss, said a person familiar with the matter. ViacomCBS stock has fallen more than 50 percent since its peak on March 22nd.

Mr. Hwang calmed down and only made a brief statement describing this as a “challenging time” for Archegos.

Kitty Bennett contributed to the research.